GC Pharma said Monday that B-Max, a high-content vitamin, has become a blockbuster drug as its annual sales exceeded 10 billion won ($9.3 million) last year.
In the Korean pharmaceutical industry, if the annual sale of a single item exceeds 10 billion won, it is classified as a blockbuster drug. The blockbuster drug designation comes five years after the company released B-Max in 2012.
“Such a feat is meaningful as the company did not place any public advertising to increase brand recognition and sales,” the company said in a statement. “It is also noteworthy that GC Pharma, which is known as a flagship business for blood products and vaccines, has developed a general drug blockbuster.”
Based on this success, GC pharma plans to expand its business to the general pharmaceutical market. The company is planning to integrate its existing OTC headquarters into its CHC (Consumer Health Care) headquarters to diversify its distribution channels and expand product range.
“The company plans to come up with a mid- to long-term strategy to reach consumers directly beyond the existing limited channels through the establishment of general distribution and online infrastructure,” a company official said.
The company will devote efforts to making more blockbuster drugs, he added.
B-Max consists of four lineups – Active, Gold, Ace, and Liquid.
<© Korea Biomedical Review, All rights reserved.>